August 30, 2016 11:01 PM ET

Biotechnology

Company Overview of CSL Ltd.

Executive Profile

Maurice A. Renshaw B.Pharm.

Independent Non Executive Director, Chairman of Innovation & Development Committee and Member of Nomination Committee, CSL Ltd.
AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 3 different industries.

See Board Relationships
69$187,179

Background

Mr. Maurice A. Renshaw, B.Pharm., previously served as Vice President at Warner-Lambert Company LLC. Mr. Renshaw serves as Director at bioCSL Inc. He has been an Independent Non Executive Director at CSL Ltd. since July 2004 and serves as Chairman of Innovation & Development Committee and Member of Nomination Committee at CSL Ltd.

Corporate Headquarters

45 Poplar Road
Parkville, Victoria 3052

Australia

Phone: 61 3 9389 1911
Fax: 61 3 9389 1434

Board Members Memberships

Director
2004-Present
Independent Non Executive Director, Chairman of Innovation & Development Committee and Member of Nomination Committee

Education

There is no Education data available.

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

Total Annual Cash Compensation$187,179
Total Calculated Compensation$187,179
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
George A. Scangos Ph.D.Chief Executive Officer and Director
Biogen Inc.
$1.5M
José E. Almeida Chairman and Chief Executive Officer
Baxter International Inc.
$231.5K
Flemming Ornskov M.D., MBA, MPHChief Executive Officer, Managing Director, Director and Chairman of Executive Committee
Shire plc
$4.3M
Víctor Grifols Roura Chairman, Chief Executive Officer and President
Grifols, S.A.
$1.4M
Yoshihiko Hatanaka Chief Executive Officer, President and Representative Director
Astellas Pharma, Inc.
$216.0M
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CSL Ltd., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.